A synthetic biology startup should plan fermentation capacity as gated purchases of evidence, because H.R. 8918, the BIO SCALE Act of 2026, has funded no facility yet.
The bill would direct the Secretary of Commerce to build at least three nonprofit, product agnostic precommercial facilities, with $345 million authorized for fiscal years 2026 to 2028 and $117 million for 2029 to 2030. Before a single tank is welded, though, Commerce owes Congress an implementation plan, then an open competition, then construction. A founder who needs 25,000 liters in 2027 cannot wait for that sequence, and the plan below is built for that founder.
The shortage the bill targets is real and it sits at the top of the size range. The most recent capacity census lists 246 fermentation facilities in more than 40 countries, and only 20 of them have tanks above 100,000 liters. If every company in that database sought the volume of its largest modeled need, the total would pass 595 million liters, over ten times what the census lists. One company that needed 50,000 to 100,000 liter batches of a nylon intermediate went to European contract plants, because few plants in the United States could run them.
Here is the part that surprises people. Tank size is the weaker lever. The same census analysis finds that each doubling of fermentation volume cuts cost of goods about 1.4 fold, while each doubling of titer cuts it twofold. So the first dollars belong to strain work and downstream recovery, and the tank comes after.
A worked example shows how the numbers move. Take a startup selling 1,000 metric tons a year at a titer of 100 grams per liter and 80 percent recovery. That is 80 kilograms per cubic meter of broth, so the company must ferment 12.5 million liters a year. Two 150,000 liter tanks running 70 batches each would cover it. Double the titer to 200 grams per liter and one tank is enough. I built that arithmetic with assumed inputs, and it carries no figure from any real plant, but it explains why a capacity plan written before the strain is finished goes stale.
The staging itself follows the facilities that exist. Stage one is bench work with small vessel models that reproduce the gradients of a large tank. Those gradients are large: mixing takes under 5 seconds in a laboratory vessel and tens to hundreds of seconds in a large one, and in one 30 cubic meter yeast fermentation the glucose near the feed port ran about ten times higher than at the bottom. Stage two is a shared pilot tank, 4,000 liters in Hayward, California or 10,000 liters near Ames, Iowa. Stage three is demonstration volume, up to 25,000 liters at the Maple Grove, Minnesota plant that BioMADE, the Pentagon and Minnesota funded with at least $132 million.
Stage four is a first commercial campaign in contract capacity, roughly 50,000 to 150,000 liters. Stage five is owned or jointly owned capacity, the kind Liberation Bioindustries designed at 600,000 liters in Richmond, Indiana, where production was expected to begin in 2026 and more than half the capacity was under contract or in advanced talks. A startup reaches stage five only when signed offtake covers the loan, because debt at 6 to 7 percent needs roughly four to five years of demand behind it, and banks generally want an offtake agreement that matches the loan term.
Each stage ends in a written gate. My own gate has four tests: titer, rate and yield hold inside a stated band across three consecutive runs; recovery is measured on whole batches; the contamination record includes a phage screen; and the cost model runs on measured inputs. Phage deserves the screen. A peer reviewed account from a commercial plant reports rapid lysis, shutdowns for repair of aseptic barriers, and a 63 to 96 percent titer loss in phage resistant strains. A tank that goes down for a month sits on your balance sheet the whole time.
In my years counseling technology companies, the clause that does the damage later is the minimum volume commitment, take or pay, signed before the process is qualified. I would tie any minimum to a qualified process, allocate failed batch cost in writing, and keep ownership of strains, data and process improvements. Shared facilities need the same care. The bill leaves contributions from non federal individuals to contract, so the startup must negotiate who owns an improvement that facility staff help make.
Federal money outside the bill may arrive sooner for some products. H.R. 7936 would have the Energy Secretary establish at least two bioindustrial facilities by September 30, 2030, with $225.5 million authorized. The House Armed Services Committee markup of the FY27 defense authorization, released June 8, 2026, adds biomanufacturing to the Industrial Base Fund in Section 1822 and creates a forward deployable biomanufacturing pilot in Section 223.
Several facts remain unknown. Will H.R. 8918 pass alone or ride on the defense bill, and at what appropriation? What fees and queue rules will the Commerce facilities adopt? Will Richmond reach full production, and at what price per liter? The next piece takes up what a tolling agreement should say about strain ownership, minimum volume commitments and who pays for a failed batch.
Interested in analysis about the intersection of tech, policy and the law? Check out my Substack channel. https://theinnovationattorney.substack.com/
